ASTELLAS PHARMA UNSP.ADR (F:YPHA) — Market Cap & Net Worth
Market Cap & Net Worth: ASTELLAS PHARMA UNSP.ADR (YPHA)
ASTELLAS PHARMA UNSP.ADR (F:YPHA) has a market capitalization of $19.55 Billion (€16.72 Billion) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #1295 globally and #289 in its home market, demonstrating a -3.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ASTELLAS PHARMA UNSP.ADR's stock price €12.90 by its total outstanding shares 1791215714 (1.79 Billion).
ASTELLAS PHARMA UNSP.ADR Market Cap History: 2020 to 2026
ASTELLAS PHARMA UNSP.ADR's market capitalization history from 2020 to 2026. Data shows growth from $22.79 Billion to $23.87 Billion (0.06% CAGR).
ASTELLAS PHARMA UNSP.ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ASTELLAS PHARMA UNSP.ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of YPHA by Market Capitalization
Companies near ASTELLAS PHARMA UNSP.ADR in the global market cap rankings as of May 4, 2026.
Key companies related to ASTELLAS PHARMA UNSP.ADR by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $862.20 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #23 globally with a market cap of $547.37 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #37 globally with a market cap of $365.30 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $862.20 Billion | $963.33 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #23 | Johnson & Johnson | NYSE:JNJ | $547.37 Billion | $227.19 |
| #37 | AbbVie Inc | NYSE:ABBV | $365.30 Billion | $206.60 |
ASTELLAS PHARMA UNSP.ADR Historical Marketcap From 2020 to 2026
Between 2020 and today, ASTELLAS PHARMA UNSP.ADR's market cap moved from $22.79 Billion to $ 23.87 Billion, with a yearly change of 0.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €23.87 Billion | +2.70% |
| 2025 | €23.24 Billion | +23.33% |
| 2024 | €18.85 Billion | -13.11% |
| 2023 | €21.69 Billion | -22.17% |
| 2022 | €27.87 Billion | +3.08% |
| 2021 | €27.04 Billion | +18.62% |
| 2020 | €22.79 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of ASTELLAS PHARMA UNSP.ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.55 Billion USD |
| MoneyControl | $19.55 Billion USD |
| MarketWatch | $19.55 Billion USD |
| marketcap.company | $19.55 Billion USD |
| Reuters | $19.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ASTELLAS PHARMA UNSP.ADR
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms… Read more